More on Discontinuation of Secondary OI Prophylaxis
In a retrospective observational study of patients treated with potent antiretroviral therapy, discontinuing maintenance therapy for CMV, MAC, toxoplasmosis, and cryptococcosis was safe, at least in patients with sustained CD4-cell recovery.
Welcome to Journal Watch. The content you requested requires sign in with a username and password.
Sign In
Sign Up
Print subscribers
Activate your free online account for full access to all site content and features.
Other visitors
Subscribe for full access to all site content and features. ($99/year)
Purchase a site pass for full access to all articles. ($19/7 days)
Or, simply register for free access to email alerts, site features, and article archives. (FREE)